Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 1.
about
Binding of human immunodeficiency virus type 1 to CD4 and CXCR4 receptors differentially regulates expression of inflammatory genes and activates the MEK/ERK signaling pathway.An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein.The envelope glycoprotein of an amphotropic murine retrovirus binds specifically to the cellular receptor/phosphate transporter of susceptible speciesDiverse CD81 Proteins Support Hepatitis C Virus InfectionAntibody potency relates to the ability to recognize the closed, pre-fusion form of HIV EnvCellular superspreaders: an epidemiological perspective on HIV infection inside the bodyA hydrophobic binding surface on the human immunodeficiency virus type 1 Nef core is critical for association with p21-activated kinase 2.Effects of CCR5 and CD4 cell surface concentrations on infections by macrophagetropic isolates of human immunodeficiency virus type 1.Mechanisms of nonrandom human immunodeficiency virus type 1 infection and double infection: preference in virus entry is important but is not the sole factorElite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kineticsRapid dissociation of HIV-1 from cultured cells severely limits infectivity assays, causes the inactivation ascribed to entry inhibitors, and masks the inherently high level of infectivity of virions.Kinetic factors control efficiencies of cell entry, efficacies of entry inhibitors, and mechanisms of adaptation of human immunodeficiency virusVariants of human immunodeficiency virus type 1 that efficiently use CCR5 lacking the tyrosine-sulfated amino terminus have adaptive mutations in gp120, including loss of a functional N-glycanHuman immunodeficiency virus type 1 attachment to HeLa CD4 cells is CD4 independent and gp120 dependent and requires cell surface heparans.Mechanisms for adaptation of simian immunodeficiency virus to replication in alveolar macrophagesInteraction with CD4 and antibodies to CD4-induced epitopes of the envelope gp120 from a microglial cell-adapted human immunodeficiency virus type 1 isolateA suicide gene approach using the human pro-apoptotic protein tBid inhibits HIV-1 replicationCellular and viral specificities of human immunodeficiency virus type 1 vif protein.Cooperation of multiple CCR5 coreceptors is required for infections by human immunodeficiency virus type 1Envelope glycoprotein determinants of neutralization resistance in a simian-human immunodeficiency virus (SHIV-HXBc2P 3.2) derived by passage in monkeys.Antigenic variation within the CD4 binding site of human immunodeficiency virus type 1 gp120: effects on chemokine receptor utilization.Increased neutralization sensitivity of CD4-independent human immunodeficiency virus variantsFrequent substitution polymorphisms in African green monkey CCR5 cluster at critical sites for infections by simian immunodeficiency virus SIVagm, implying ancient virus-host coevolutionAdaptive mutations in the V3 loop of gp120 enhance fusogenicity of human immunodeficiency virus type 1 and enable use of a CCR5 coreceptor that lacks the amino-terminal sulfated regionAdoption of an "open" envelope conformation facilitating CD4 binding and structural remodeling precedes coreceptor switch in R5 SHIV-infected macaques.Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaquesSegregation of CD4 and CXCR4 into distinct lipid microdomains in T lymphocytes suggests a mechanism for membrane destabilization by human immunodeficiency virusCoreceptor phenotype of natural human immunodeficiency virus with nef deleted evolves in vivo, leading to increased virulence.The number of CCR5 expressing CD4+ T lymphocytes is lower in HIV-infected long-term non-progressors with viral control compared to normal progressors: a cross-sectional study.Second-site compensatory mutations of HIV-1 capsid mutations.Elevated expression of GM3 in receptor-bearing targets confers resistance to human immunodeficiency virus type 1 fusion.Determinants of human immunodeficiency virus type 1 entry in the CDR2 loop of the CD4 glycoprotein.Replicative function and neutralization sensitivity of envelope glycoproteins from primary and T-cell line-passaged human immunodeficiency virus type 1 isolates.Human plasma enhances the infectivity of primary human immunodeficiency virus type 1 isolates in peripheral blood mononuclear cells and monocyte-derived macrophages.Processing of the envelope glycoprotein gp160 in immunotoxin-resistant cell lines chronically infected with human immunodeficiency virus type 1.Vaccination protects against in vivo-grown feline immunodeficiency virus even in the absence of detectable neutralizing antibodies.CD4, CXCR-4, and CCR-5 dependencies for infections by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1.Selective employment of chemokine receptors as human immunodeficiency virus type 1 coreceptors determined by individual amino acids within the envelope V3 loopPolymorphisms in the CCR5 genes of African green monkeys and mice implicate specific amino acids in infections by simian and human immunodeficiency virusesCD4 and MHC-I downregulation are conserved in primary HIV-1 Nef alleles from brain and lymphoid tissues, but Pak2 activation is highly variable
P2860
Q24523390-EC3B9625-43F6-4509-B0E6-AB09D96FFB13Q24523705-F5E39C4B-F3C2-4127-B321-BCC735F10F7FQ24675131-759910FB-71E9-43D3-AE98-6EA0F8425E4EQ27477625-1D457327-1BAD-483F-AB0B-3A70A5CA499CQ28256508-C759E8E0-C5EF-44FA-8192-D75E07BA7156Q28657772-D9231B78-79C9-4C66-8047-5DDBC95E858FQ28768294-D54F54D6-B0B3-4556-B635-41685BDD53C6Q29622903-9A4416A0-E89F-4AF9-836C-A46E6A0A3709Q30448451-1A893498-87CC-435C-9BB1-F7EAC3E5AAC3Q33429049-DCD233A8-CC6F-4AC0-B706-0FA3F0F55C8CQ33676520-1352CB40-5460-410A-8AD1-61299F0472FFQ33707328-1EA7C78D-101C-4F21-AACE-525E5A2212E7Q33707333-17FA8268-1C68-442F-BCF6-C79797095C7CQ33782608-A3937A5B-0626-485B-9993-4A17C1645F72Q33787402-8928DBAF-763D-4178-A14E-4A86A5CF9CDEQ33788874-332CCC7F-9E66-4C5A-869D-9870B95FED02Q33790492-F285E335-ECAD-47BF-974B-098091C41BA9Q33806688-D4D9B47F-7DD1-44F8-A5BC-001B33786C3AQ33808920-C82F8B8B-7942-48E8-B69A-F345094B4260Q33839485-1D040F79-DB00-4290-97AE-F3F703731DDDQ33841969-96EA6274-0119-4AFD-87B6-54E827A513C8Q33850415-D1254FC2-33A7-4268-807D-3778F4266202Q33854213-7D2B953C-F845-4166-996C-16EB1A44F293Q33870292-92CAC794-11D2-473B-A7D0-6EC5EF7B2B8CQ33961448-00919E89-F1B0-463A-AC92-91ADF11D1899Q34154514-7366ABE9-F3AE-43F7-B85A-D4CAC3C7EDB0Q34330529-7BBF7EFE-16B1-4D2F-A230-4D01CD23B94DQ34342429-A8C239EC-C86A-4435-8B67-5DEE8712E964Q34740235-6B441524-4D44-47FB-B899-E756E72E5A1BQ35076692-4C41F616-90B9-49AF-845C-F4F5AFC4B5FEQ35122813-FF815D30-DE9E-40F0-B21A-5FF4EF1B25E1Q35829099-C59390ED-3404-4E1A-8A20-3FF4C9CBA227Q35841780-04553154-F472-44E2-A901-903EEBA03E5EQ35847492-650D8356-1A11-4AED-837E-A6C72F813588Q35851143-331B85FD-34FC-478E-9A0E-9AFC862036B1Q35854001-2D4F32D3-C774-45BF-83AB-ACA1FA19A85AQ35876191-98492613-8E51-4F47-8D99-698D1E2B3218Q35893615-A488DE0E-B6E8-44EC-B198-E7B2661E02FAQ35898770-DD1870CA-4408-4EA6-AA4F-5398752FDA83Q36015423-68A6A00B-9EA7-4659-9399-07CEE9D1BAB2
P2860
Differences in CD4 dependence for infectivity of laboratory-adapted and primary patient isolates of human immunodeficiency virus type 1.
description
1994 nî lūn-bûn
@nan
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
1994年论文
@zh
1994年论文
@zh-cn
name
Differences in CD4 dependence ...... immunodeficiency virus type 1.
@ast
Differences in CD4 dependence ...... immunodeficiency virus type 1.
@en
type
label
Differences in CD4 dependence ...... immunodeficiency virus type 1.
@ast
Differences in CD4 dependence ...... immunodeficiency virus type 1.
@en
prefLabel
Differences in CD4 dependence ...... immunodeficiency virus type 1.
@ast
Differences in CD4 dependence ...... immunodeficiency virus type 1.
@en
P2093
P2860
P1433
P1476
Differences in CD4 dependence ...... immunodeficiency virus type 1
@en
P2093
P2860
P304
P407
P577
1994-04-01T00:00:00Z